NCT07814404尚未招募1 期
An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 10
- 主要终点
- Total Recovery (Urine + Feces) of the Administered Radioactivity
研究概览
简要总结
This study is conducted to assess the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of [14C]-INCB161734 in healthy male participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males aged 19 to 55 years (inclusive) at the time of signing the ICF.
- •Body mass index between 18.0 and 32.0 kg/m2 (inclusive).
- •Ability to swallow and retain oral medication.
排除标准
- •History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.
- •Resting pulse < 40 bpm or > 100 bpm, confirmed by repeat testing at screening.
- •History or presence of an abnormal ECG before initial dose administration that, in the investigator's opinion, is clinically significant (QTcF interval > 450 milliseconds [may increase the risk associated with participating in the study or may confound ECG data analysis], QRS interval > 120 milliseconds, and PR interval > 220 milliseconds).
- •Presence of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis).
- •History of irregular bowel movements (eg, irritable bowel syndrome, frequent episodes of diarrhea, or constipation defined by less than 1 bowel movement on average per 2 days) or lactose intolerant.
- •History of malignancy within 5 years of screening, with the exception of cured basal cell or squamous cell carcinoma of the skin, ductal carcinoma in situ, or prostate cancer.
- •Current or recent (≤ 6 months of screening), clinically significant gastrointestinal disease or surgery or any history of gastrointestinal surgery (including cholecystectomy, excluding appendectomy and uncomplicated hernia repair) that is anticipated to affect the absorption of study treatment.
- •Any major surgery within ≤ 6 months of screening.
- •Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for plasma only).
- •Blood transfusion within 4 weeks of check-in.
- •Positive test for hepatitis B virus, HCV, or HIV.
- •Note: Participants whose results are compatible with prior immunization or immunity due to infection for hepatitis B may be included at the discretion of the investigator.
- •History of significant alcohol use within 3 months of screening, defined as regular alcohol consumption > 21 units per week (1 unit = ½ pint beer or a 25-mL shot of 40% spirit, 1.5 to 2 units = 125-mL glass of wine, depending on type).
- •Positive urine or breath test for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
- •Exposure to significant diagnostic or therapeutic radiation (eg, serial x-ray, computed tomography scan, barium meal) or employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
- •History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
- •Known hypersensitivity or severe reaction to INCB161734 or any excipients of INCB161734 (refer to the IB).
- •Use of tobacco- or nicotine-containing products within 1 month of screening.
- •eGFR < 90 mL/min/1.73 m2 based on the site's preferred formula at screening. • Note: Assessment of eGFR may be repeated once if outside of the reference range.
- •Other protocol-defined Inclusion/Exclusion Criteria may apply.
研究组 & 干预措施
INCB161734
Experimental
Participants will be administered orally a dose solution consisting of INCB161734 and radiolabeled INCB161734.
干预措施: INCB161734 (Drug)
结局指标
主要结局
Total Recovery (Urine + Feces) of the Administered Radioactivity
时间窗: Up to 2 weeks
Radioactivity in urine and feces was reported as the percentage of the administered radioactivity excreted.
Percentage of total radioactive dose in Plasma, Urinary and Fecal Excretion
时间窗: Up to 2 weeks
To characterize the metabolic profile and identify circulating and excreted metabolites of INCB161734.
次要结局
- PK for plasma INCB123667: Cmax(Up to 2 weeks)
- PK for plasma INCB123667: tmax(Up to 2 weeks)
- PK for plasma INCB123667: AUClast(Up to 2 weeks)
- PK for plasma INCB123667: AUCinf(Up to 2 weeks)
- PK for plasma INCB123667: t½(Up to 2 weeks)
- PK for plasma INCB123667: CL/F(Up to 2 weeks)
- PK for plasma INCB123667: Vz/F(Up to 2 weeks)
- PK for urine INCB123667: Ae(Up to 2 weeks)
- PK for urine INCB123667: CLR(Up to 2 weeks)
- PK for urine INCB123667: %fe(Up to 2 weeks)
- PK for whole blood and plasma total radioactivity: Cmax(Up to 2 weeks)
- PK for whole blood and plasma total radioactivity: tmax(Up to 2 weeks)
- PK for whole blood and plasma total radioactivity: AUClast(Up to 2 weeks)
- PK for whole blood and plasma total radioactivity: AUCinf(Up to 2 weeks)
- PK for whole blood and plasma total radioactivity: t½(Up to 2 weeks)
- Treatment Emergent Adverse Events (TEAEs)(Up to approximately 2 months)
研究者
相似试验
已完成
1 期
Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019NCT07479745Grünenthal GmbH10
招募中
1 期
Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184HIV InfectionsNCT07636928ViiV Healthcare9
尚未招募
1 期
A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male AdultsSchizophreniaNCT07455084Otsuka Pharmaceutical Development & Commercialization, Inc.8
尚未招募
1 期
A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954Healthy ParticipantsNCT07812077AstraZeneca16
招募中
1 期
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)2024-513708-33-00Sutro Biopharma Inc.20